2. Search Result
Search Result
Results for "

LRRK2 kinase

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

2

Peptides

1

Recombinant Proteins

3

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12282
    GNE-9605

    		LRRK2 Neurological Disease
    GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
    GNE-9605
  • HY-108886
    JWG-071
    5 Publications Verification

    		 ERK Cancer
    JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC50 values of 88nM and 109 nM, respectively .
    JWG-071
  • HY-120085
    PFE-360
    3 Publications Verification

    PF-06685360

    		 LRRK2 Neurological Disease
    PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo .
    PFE-360
  • HY-152107
    LRRK2-IN-7

    		LRRK2 Neurological Disease
    LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .
    LRRK2-IN-7
  • HY-P5979
    LRRKtide

    		LRRK2 Neurological Disease
    LRRKtide is a polypeptide substrate. LRRKtide is a specific phosphorylation substrate of LRRK2, a kinase associated with Parkinson's disease, and its phosphorylation site is a threonine residue. LRRKtide can be used for characterization of the catalytic properties of LRRK2, as well as studies on kinase activity and inhibition. LRRKtide is applicable to research related to Parkinson's disease .
    LRRKtide
  • HY-112855
    PF-06454589

    		LRRK2 Neurological Disease
    PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .
    PF-06454589
  • HY-134562
    PF-06371900

    		LRRK2 Neurological Disease
    PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .
    PF-06371900
  • HY-112809
    GSK2646264

    		Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase Inflammation/Immunology
    GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .
    GSK2646264
  • HY-174427
    RN341

    		LRRK2 Neurological Disease
    RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM). RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.
    RN341
  • HY-174420
    RN277

    		LRRK2 Neurological Disease
    RN277 is an inhibitor for LRRK2 type II kinase. RN277 can be used as a cellular tool targeting the LRRK2 inactive state. RN277 can inhibit LRRK1 kinase activity in vitro. RN277 inhibits LRRK2 kinase activity in vitro (IC50 = 70 nM). RN277 reduces phosphorylation of Rab8a dose-dependently. RN277 can be studied in research for Parkingson’s disease .
    RN277
  • HY-148353
    PF-06455943

    		LRRK2 Neurological Disease
    PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC50 value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .
    PF-06455943
  • HY-152107A
    (R,R)-LRRK2-IN-7

    		LRRK2 Neurological Disease
    (R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.
    (R,R)-LRRK2-IN-7
  • HY-144074
    LRRK2-IN-4

    		LRRK2 Neurological Disease
    LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .
    LRRK2-IN-4
  • HY-P10636
    Nictide

    		LRRK2 Others
    Nictide is a peptide substrate of LRRK2 (leucine-rich repeat protein kinase-2). Nictide can be phosphorylated by the activated LRRK2[G2019S] with a Km of 10 μM .
    Nictide
  • HY-151444
    LRRK2-IN-6

    		LRRK2 Neurological Disease
    LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .
    LRRK2-IN-6
  • HY-151441
    LRRK2-IN-5

    		LRRK2 Neurological Disease
    LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .
    LRRK2-IN-5
  • HY-169576
    LRRK2-IN-16

    		LRRK2 Neurological Disease Inflammation/Immunology
    LRRK2-IN-16 (compound 25) is a LRRK2 kinase inhibitor with an IC50 < 5 μM. LRRK2-IN-16 can be utilized in neurodegenerative disorders and autoimmune disorders research .
    LRRK2-IN-16
  • HY-172952
    LRRK2-IN-17

    		LRRK2 RET Neurological Disease Cancer
    LRRK2-IN-17 (Compound 6) is an orally active LRRK2 inhibitor (IC50: 3.5 and 3.3 nM for WT and G2019S, respectively). LRRK2-IN-17 inhibits RET kinase (IC50: 59 nM). LRRK2-IN-17 can be used in cancer and Parkinson's disease (PD) research .
    LRRK2-IN-17
  • HY-156167
    LRRK2-IN-10

    		LRRK2 Neurological Disease
    LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant G2019S-LRRK2 kinase inhibitor with IC50s of 11 nM and 5.2 nM for G2019S-LRRK2 pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research .
    LRRK2-IN-10
  • HY-75368
    SRI-31255

    		LRRK2 Neurological Disease
    SRI-31255 is an orally active LRRK2 inhibitor with IC50 values of 520 and 427 nM for human wild-type (WT) and mutant G2019S, respectively. SRI-31255 exerts neuroprotective effects by binding to the ATP-binding pocket of LRRK2, inhibiting kinase activity. SRI-31255 can be used as a lead compound for the development of LRRK2-targeted drugs for the treatment of Parkinson's disease .
    SRI-31255
  • HY-165543
    SRI-29132

    		LRRK2 Neurological Disease
    SRI-29132 is a potent leucine-rich repeat kinase 2 (LRRK2) inhibitor. SRI-29132 is promising for research of Parkinson’s disease .
    SRI-29132
  • HY-182928
    LRRK2-IN-21

    		LRRK2 Mps1 Neurological Disease
    LRRK2-IN-21 is a selective, blood-brain barrier-permeable LRRK2 kinase inhibitor with an IC50 of 0.35 nM. LRRK2-IN-21 inhibits TTK kinase with an IC50 of 70 nM. LRRK2-IN-21 is applicable to the research of Parkinson's disease .
    LRRK2-IN-21
  • HY-161571
    LRRK2-IN-13

    		LRRK2 Neurological Disease
    LRRK2-IN-13 (Compound 13) is an inhibitor of LRRK2 (IC50=0.57 nM). LRRK2-IN-13 has brain penetrating properties .
    LRRK2-IN-13
  • HY-171801
    PROTAC LRRK2 Degrader-1

    		PROTACs LRRK2 Neurological Disease
    PROTAC LRRK2 Degrader-1 (compound 18) is a leucine-rich repeat kinase 2 (LRRK2) PROTAC degrader with an IC 50 value less than 10 nM. PROTAC LRRK2 Degrader-1 can be used in the research of Parkinson's disease .
    PROTAC LRRK2 Degrader-1
  • HY-181046
    Multi-kinase-IN-14

    		α-synuclein Bcr-Abl GSK-3 DYRK LRRK2 Microtubule/Tubulin Neurological Disease
    Multi-kinase-IN-14 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Multi-kinase-IN-14 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Multi-kinase-IN-14 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease .
    Multi-kinase-IN-14
  • HY-108886R
    JWG-071 (Standard)

    		Reference Standards ERK Cancer
    JWG-071 (Standard) is the analytical standard of JWG-071 (HY-108886). This product is intended for research and analytical applications. JWG-071 is the Kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC50 values of 88nM and 109 nM, respectively .
    JWG-071 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: